Tzourio C, Arima H, Harrap S, Anderson C, Godin O, Woodward M, Neal B, Bousser M-G, Chalmers J, Cambien F, MacMahon S
INSERM U708, 75651 Paris cedex 13, France.
Neurology. 2008 Apr 15;70(16):1322-8. doi: 10.1212/01.wnl.0000308819.43401.87. Epub 2008 Feb 6.
The apolipoprotein E (APOE) polymorphism is an established risk factor for intracerebral hemorrhage (ICH) that is related to cerebral amyloid angiopathy in the white population. Among Asian populations, although ICH represents up to one third of all strokes and has high rates of mortality and morbidity, the role of the APOE polymorphism has not been well studied.
The Perindopril Protection Against Recurrent Stroke Study (PROGRESS) was a randomized, double-blind, placebo-controlled trial of a blood pressure lowering regimen in subjects with prior cerebrovascular disease. APOE status was determined for 5,671 patients, including 2,148 Asians (38%).
During the 3.9 years of follow-up, ICH occurred in 99 patients. Overall, carrying an epsilon 2 or epsilon 4 allele of the APOE polymorphism was associated with an adjusted hazard ratio (HR(a)) of 1.85 (95% CI = 1.24 to 2.76). In Asian patients the risk of ICH for epsilon 2 or epsilon 4 carriers was 2.11 (95% CI = 1.28 to 3.47) and 1.48 (95% CI = 0.76 to 2.87) in Europeans. Carriers of the epsilon 2 or epsilon 4 allele had an increased risk of both incident and recurrent ICH, and both cortical and deep ICH, and most risk estimates were higher in Asians than in Europeans. For both ethnic groups and for subtypes of ICH active treatment more than halved the risk of ICH and the treatment effects were not different in carriers of the epsilon 2 or epsilon 4 allele and in those with the epsilon 3 epsilon 3 genotype.
There is a strong association between APOE genotype and the risk of intracerebral hemorrhage (ICH). In Asian patients the role of APOE polymorphisms in ICH is much broader than was previously supposed.
载脂蛋白E(APOE)基因多态性是脑出血(ICH)的一个既定风险因素,在白种人群中与脑淀粉样血管病相关。在亚洲人群中,尽管脑出血占所有中风的三分之一,且死亡率和发病率很高,但APOE基因多态性的作用尚未得到充分研究。
培哚普利预防复发性中风研究(PROGRESS)是一项针对既往有脑血管疾病患者的降压方案的随机、双盲、安慰剂对照试验。对5671名患者进行了APOE状态测定,其中包括2148名亚洲人(38%)。
在3.9年的随访期间,99名患者发生了脑出血。总体而言,携带APOE基因多态性的ε2或ε4等位基因与调整后的风险比(HR(a))为1.85(95%CI = 1.24至2.76)相关。在亚洲患者中,ε2或ε4携带者发生脑出血的风险为2.11(95%CI = 1.28至3.47),在欧洲人中为1.48(95%CI = 0.76至2.87)。ε2或ε4等位基因的携带者发生首次和复发性脑出血以及皮质和深部脑出血的风险均增加,大多数风险估计值在亚洲人中高于欧洲人。对于两个种族群体和脑出血亚型,积极治疗使脑出血风险降低了一半以上,并且在ε2或ε4等位基因携带者和ε3ε3基因型患者中治疗效果没有差异。
APOE基因型与脑出血(ICH)风险之间存在密切关联。在亚洲患者中,APOE基因多态性在脑出血中的作用比以前认为的要广泛得多。